Table 1

Pathologic and clinical characteristics of tumors diagnosed in the PCPT stratified by grade and treatment group

CharacteristicGleason ≤6Gleason 7Gleason ≥8
Finasteride (n = 389)Placebo (n = 711)Finasteride (n = 191)Placebo (n = 187)Finasteride (n = 91)Placebo (n = 57)
Mean (SD)Med (10-90%)Mean (SD)Med (10-90%)Mean (SD)Med (10-90%)Mean (SD)Med (10-90%)Mean (SD)Med (10-90%)Mean (SD)Med (10-90%)
No. cores positive*1.40 (0.71)1 (1-2)1.55 (0.93)1 (1-3)1.99 (1.03)2 (1-3)2.36 (1.53)2 (1-4)2.59 (1.77)2 (1-4.5)2.98 (1.91)3 (1-5)
Percent cores positive22.1 (11.3)16.7 (12.5-37.5)23.9 (13.7)16.7 (12.5-41.4)31.2 (16.4)33.3 (14.3-50.0)36.7 (20.3)33.3 (16.7-66.7)38.4 (20.5)33.3 (16.7-61.1)43.3 (23.8)45.0 (16.7-80.0)
Greatest linear extent (mm)1.76 (1.53)1.30 (0.50-3.50)1.95 (1.75)1.30 (0.50-4.40)4.13 (3.04)3.20 (1.00-8.40)4.56 (3.16)4.00 (1.30-9.00)4.97 (2.95)4.50 (1.50-9.00)5.45 (3.62)4.50 (1.50-10.10)
Aggregate linear extent (mm)2.31 (2.68)1.40 (0.50-5.00)2.72 (3.20)1.60 (0.50-6.40)6.66 (6.16)4.50 (1.00-14.90)8.18 (8.07)5.50 (1.50-18.50)9.61 (10.88)6.20 (1.50-21.00)12.37 (13.52)7.25 (2.00-36.00)
Bilateral (%)11.114.220.026.328.644.6
Perineural invasion (%)4.45.316.321.09.917.9
Median prostate volume (cm3)§23.832.725.133.523.838.8
Median adjusted PSA (ng/mL)1.802.003.403.704.804.60
Median PSA density (ng/mL/g)0.070.060.130.090.190.12
Median total biopsy cores666666
Insignificant cancer (%; criteria 1)36.038.40000
Insignificant cancer (%; criteria 2)**38.542.20000
  • * Comparison of number of cores positive significant for Gleason ≤6 (P = 0.024, Kruskal-Wallis test).

  • Comparison of percent cores positive significant for Gleason 7 (P = 0.009, Kruskal-Wallis test).

  • Comparison of percent bilateral significant for Gleason 8-10 (P = 0.047, χ2 test).

  • § Comparison of median prostate volume significant in all subgroups (P < 0.001 for all three, Kruskal-Wallis test).

  • Comparison of median PSA density significant in all subgroups [P < 0.001 (Gleason 6), P < 0.001 (Gleason 7), and P = 0.002 (Gleason 8-10), Kruskal-Wallis test].

  • Stage T1c + PSA density <0.15 ng/mL/g + Gleason score ≤6 (no pattern 4 or 5) + tumor limited to <3 cores + no core with >50% involvement.

  • ** Stage T1c + PSA density <0.15 ng/mL/g + Gleason score ≤6 (no pattern 4 or 5) + tumor limited to <3 mm on 1 core.